BHEKISISA: A R60 test could help SA find millions more TB patients — but will it miss the most dangerous cases?

South Africa faces a critical strategic decision in tuberculosis management that carries significant implications for healthcare investors and multinational health-tech companies operating across Africa. The nation is piloting a R60 (approximately €3.20) rapid TB test as an alternative to more expensive diagnostic standards, presenting a classic public health dilemma: expanding screening reach versus maintaining diagnostic precision for dangerous pathogenic variants.

The epidemiological context is sobering. South Africa bears approximately 10% of the world's TB burden, with an estimated 310,000 new TB cases annually. Drug-resistant TB (DR-TB) represents a growing crisis, with multidrug-resistant and extensively drug-resistant strains driving treatment failures and mortality. The proposed low-cost test addresses a genuine access barrier—current gold-standard diagnostics cost considerably more and require sophisticated laboratory infrastructure unavailable in many resource-constrained settings. For European investors in healthcare delivery and diagnostics distribution, this represents both opportunity and risk.

The economic logic appears sound on surface analysis. A R60 test dramatically increases screening capacity in primary care clinics, community health centers, and mobile health units. If implemented nationally, it could identify millions of additional TB cases currently missed due to cost and access barriers. Earlier case detection theoretically improves treatment outcomes and reduces transmission chains. However, the test's inability to detect drug-resistant strains introduces a dangerous blind spot. Patients with undiagnosed DR-TB may receive standard first-line therapy, develop treatment failure, and become vectors for harder-to-treat variants.

This creates a two-tiered diagnostic risk. High-burden, low-resource clinics using the cheap test may achieve impressive screening numbers while inadvertently allowing drug-resistant cases to progress unchecked. This generates downstream costs in second-line treatment, hospitalization, and mortality that ultimately exceed the savings from cheaper initial diagnostics. For healthcare systems already burdened by DR-TB management costs, this represents false economy.

The market implications are substantial. Companies in rapid diagnostics, laboratory automation, and telemedicine platforms see expansion opportunities in South Africa's healthcare infrastructure. However, widespread adoption of diagnostically limited tests could fragment the market, creating demand for expensive confirmatory testing and creating inefficiencies. International donors and development finance institutions will scrutinize implementation data carefully—any evidence of worsening DR-TB outcomes would trigger regulatory skepticism across African TB control programs.

South Africa's decision becomes a regional bellwether. If the pilot demonstrates that cheap screening followed by targeted confirmatory testing for high-risk populations yields better outcomes than current status quo, the model could scale across Southern Africa. Conversely, if DR-TB cases slip through detection, it validates arguments for integrated diagnostic platforms that detect both susceptible and resistant strains at point-of-care costs approaching the low-cost test.

The resolution likely involves hybrid approaches: mass screening with the cheap test, coupled with reflex testing protocols for symptomatic patients and populations with DR-TB risk factors. This maintains screening reach while preserving diagnostic accuracy where it matters most. Healthcare technology investors should monitor pilot outcomes closely, as the data will determine which diagnostic platforms receive procurement preferences across Africa's health systems.

---